Allergy alerting and overrides for opioid analogues across two health systems

Objectives Despite opioids comprising a majority of drug allergy alert (DAA) overrides, few studies have designed recommendations for clinical decision support (CDS) systems. We determined the frequency of opioid analogue DAA overrides and assessed DAAs overridden by patient and provider type, the m...

Full description

Saved in:
Bibliographic Details
Main Authors: David W Bates, Li Zhou, Kimberly G Blumenthal, Diane L Seger, Rachel L Wasserman, Heba H Edrees, Foster R Goss, Ying-Chih Lo, Sheril Varghese, Liqin Wang, Suzanne Blackley
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:BMJ Health & Care Informatics
Online Access:https://informatics.bmj.com/content/32/1/e101259.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850125168890871808
author David W Bates
Li Zhou
Kimberly G Blumenthal
Diane L Seger
Rachel L Wasserman
Heba H Edrees
Foster R Goss
Ying-Chih Lo
Sheril Varghese
Liqin Wang
Suzanne Blackley
author_facet David W Bates
Li Zhou
Kimberly G Blumenthal
Diane L Seger
Rachel L Wasserman
Heba H Edrees
Foster R Goss
Ying-Chih Lo
Sheril Varghese
Liqin Wang
Suzanne Blackley
author_sort David W Bates
collection DOAJ
description Objectives Despite opioids comprising a majority of drug allergy alert (DAA) overrides, few studies have designed recommendations for clinical decision support (CDS) systems. We determined the frequency of opioid analogue DAA overrides and assessed DAAs overridden by patient and provider type, the most common allergic reactions documented in electronic health records (EHR), reaction severity, and associated hypersensitivity.Methods We conducted an observational cross-sectional study of DAAs in two geographically remote health systems. Patients were included if they were 18 years or older and had an opioid DAA generated when a medication was ordered. Patient and provider demographics, drug allergies, medication ordered, alert overrides, drug allergy reactions and DAA history were collected. Opioid analogue allergies were analysed by reaction type documented in the EHR, reaction severities (high, medium or low) and hypersensitivity reaction. Based on these factors, alerts were recommended to be interruptive requiring a coded response or changed to be non-interruptive (informational).Results There were 700 493 alerts concerning opioid analogues fired for 50 527 patients across both sites, and 71.8% of these alerts were overridden. Nearly three-quarters of overridden reactions had a low to medium severity level at both institutions. Only 29.3% of the overridden alerts were truly immune-mediated.Discussion Our recommendations would reduce interruptive alerts in half by converting them to non-interruptive alerts (46.4%). The data suggest opportunities to improve opioid-related CDS systems.Conclusions We evaluated overrides of opioids and used this data to suggest ways to redesign DAAs to decrease alert override rates, combat alert fatigue and improve patient safety.
format Article
id doaj-art-0ea3e66a32bf4274b64ecd4bfe247b9a
institution OA Journals
issn 2632-1009
language English
publishDate 2025-05-01
publisher BMJ Publishing Group
record_format Article
series BMJ Health & Care Informatics
spelling doaj-art-0ea3e66a32bf4274b64ecd4bfe247b9a2025-08-20T02:34:10ZengBMJ Publishing GroupBMJ Health & Care Informatics2632-10092025-05-0132110.1136/bmjhci-2024-101259Allergy alerting and overrides for opioid analogues across two health systemsDavid W Bates0Li Zhou1Kimberly G Blumenthal2Diane L Seger3Rachel L Wasserman4Heba H Edrees5Foster R Goss6Ying-Chih Lo7Sheril Varghese8Liqin Wang9Suzanne Blackley10Harvard Medical School, Boston, Massachusetts, USADepartment of General Surgery, Peking Union Medical College Hospital, Beijing, Beijing, ChinaDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA3 Clinical and Quality Analysis, Mass General Brigham, Somerville, Massachusetts, USAMassachusetts College of Pharmacy and Health Sciences, MCPHS University, Boston, Massachusetts, USA1 Department of Medicine, Brigham and Women`s Hospital, Boston, Massachusetts, USADepartment of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USADepartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USAObjectives Despite opioids comprising a majority of drug allergy alert (DAA) overrides, few studies have designed recommendations for clinical decision support (CDS) systems. We determined the frequency of opioid analogue DAA overrides and assessed DAAs overridden by patient and provider type, the most common allergic reactions documented in electronic health records (EHR), reaction severity, and associated hypersensitivity.Methods We conducted an observational cross-sectional study of DAAs in two geographically remote health systems. Patients were included if they were 18 years or older and had an opioid DAA generated when a medication was ordered. Patient and provider demographics, drug allergies, medication ordered, alert overrides, drug allergy reactions and DAA history were collected. Opioid analogue allergies were analysed by reaction type documented in the EHR, reaction severities (high, medium or low) and hypersensitivity reaction. Based on these factors, alerts were recommended to be interruptive requiring a coded response or changed to be non-interruptive (informational).Results There were 700 493 alerts concerning opioid analogues fired for 50 527 patients across both sites, and 71.8% of these alerts were overridden. Nearly three-quarters of overridden reactions had a low to medium severity level at both institutions. Only 29.3% of the overridden alerts were truly immune-mediated.Discussion Our recommendations would reduce interruptive alerts in half by converting them to non-interruptive alerts (46.4%). The data suggest opportunities to improve opioid-related CDS systems.Conclusions We evaluated overrides of opioids and used this data to suggest ways to redesign DAAs to decrease alert override rates, combat alert fatigue and improve patient safety.https://informatics.bmj.com/content/32/1/e101259.full
spellingShingle David W Bates
Li Zhou
Kimberly G Blumenthal
Diane L Seger
Rachel L Wasserman
Heba H Edrees
Foster R Goss
Ying-Chih Lo
Sheril Varghese
Liqin Wang
Suzanne Blackley
Allergy alerting and overrides for opioid analogues across two health systems
BMJ Health & Care Informatics
title Allergy alerting and overrides for opioid analogues across two health systems
title_full Allergy alerting and overrides for opioid analogues across two health systems
title_fullStr Allergy alerting and overrides for opioid analogues across two health systems
title_full_unstemmed Allergy alerting and overrides for opioid analogues across two health systems
title_short Allergy alerting and overrides for opioid analogues across two health systems
title_sort allergy alerting and overrides for opioid analogues across two health systems
url https://informatics.bmj.com/content/32/1/e101259.full
work_keys_str_mv AT davidwbates allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT lizhou allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT kimberlygblumenthal allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT dianelseger allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT rachellwasserman allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT hebahedrees allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT fosterrgoss allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT yingchihlo allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT sherilvarghese allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT liqinwang allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems
AT suzanneblackley allergyalertingandoverridesforopioidanaloguesacrosstwohealthsystems